Memorial Sloan Kettering Cancer Center
Tumor-infiltrating lymphocyte cell therapy ‘potentially viable’ option for advanced NSCLC
Nearly a quarter of patients with heavily pretreated non-small cell lung cancer achieved an objective response to an infusion of LN-145, according to study results presented at Society for the Immunotherapy of Cancer Annual Meeting.
Regimen ‘highly active’ among certain patients with non-clear cell renal cell carcinoma
The combination of cabozantinib and nivolumab showed promising efficacy for certain patients with metastatic non-clear cell renal cell carcinoma, according to phase 2 study results presented at International Kidney Cancer Symposium.
Oncologists reflect on innovations, challenges, ‘eye-opening’ experiences of past year
From innovations in therapy and telehealth to greater recognition of structural barriers to care and the need for community outreach, developments in oncology over the past year will have a lasting impact, experts said.
CAR T-cell therapy linked to cardiovascular, pulmonary adverse effects
Chimeric antigen receptor T-cell therapy appeared associated with various cardiovascular and pulmonary adverse events, according to results of a retrospective pharmacovigilance study.
CAR-T plus pembrolizumab ‘promising’ for malignant pleural mesothelioma
Chimeric antigen receptor T-cell therapy followed by pembrolizumab appeared safe and feasible for patients with malignant pleural mesothelioma, phase 1 trial results published in Cancer Discovery showed.
Memorial Sloan Kettering names department chair
Deborah Schrag, MD, MPH, has been appointed chair of the department of medicine at Memorial Sloan Kettering Cancer Center.
Tremelimumab-durvalumab regimen extends OS in unresectable HCC
The addition of tremelimumab to first-line durvalumab significantly improved OS compared with sorafenib for certain patients with unresectable hepatocellular carcinoma, according to topline data released by the agent’s manufacturer.
2-year data confirm benefit of nivolumab regimen for advanced gastric, esophageal cancers
The addition of nivolumab to chemotherapy showed durable benefit for treatment-naive patients with advanced gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma, 2-year data from the CheckMate 649 study showed.
Hodgkin lymphoma: Improving short-, long-term risks of treatment
CAD risk may be elevated in women with left-sided radiation for breast cancer
The risk for CAD in women with stage I or II breast cancer who received left-sided radiation therapy may be more than twofold greater compared with those who received right-sided radiation.